Phigenix's Tissue-based Biomarker DEFB1 Correlates with Risk of Developing Prostate Cancer

Written By Carlton Donald

In a recent study, Human beta defensin-1 (DEFB1) loss was observed in 95.6% of Gleason 3 and 90% of Gleason 4 biopsies, and it was concluded that DEFB1 loss is a useful indicator to identify patients with high risk of developing prostate cancer (Hong et al., APMIS. 2017 Sep 8). Phigenix is currently developing a DEFB1-based diagnostic test for prostate cancer.

Carlton Donald
Previous

Phigenix is Featured in The Atlanta Business Chronicle
Next

Study Finds that the Phigenix Prostate Cancer Screening Biomarker is Detectable in Urine